IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track…
Browsing Tag